George C. Prendergast

25.1k total citations · 7 hit papers
226 papers, 19.1k citations indexed

About

George C. Prendergast is a scholar working on Molecular Biology, Oncology and Biological Psychiatry. According to data from OpenAlex, George C. Prendergast has authored 226 papers receiving a total of 19.1k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Molecular Biology, 57 papers in Oncology and 55 papers in Biological Psychiatry. Recurrent topics in George C. Prendergast's work include Tryptophan and brain disorders (55 papers), Cancer-related Molecular Pathways (33 papers) and Protein Kinase Regulation and GTPase Signaling (32 papers). George C. Prendergast is often cited by papers focused on Tryptophan and brain disorders (55 papers), Cancer-related Molecular Pathways (33 papers) and Protein Kinase Regulation and GTPase Signaling (32 papers). George C. Prendergast collaborates with scholars based in United States, United Kingdom and Germany. George C. Prendergast's co-authors include Alexander J. Muller, James B. DuHadaway, Edward B. Ziff, Peter F. Lebowitz, Daitoku Sakamuro, Richard Metz, William P. Malachowski, Erika Sutanto‐Ward, Lisa D. Laury‐Kleintop and Preston S. Donover and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

George C. Prendergast

224 papers receiving 18.8k citations

Hit Papers

Inhibition of indoleamine 2,3-dioxygenase, an immuno... 1991 2026 2002 2014 2005 1993 1998 1991 1991 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
    2005 873 citations Alexander J. Muller, James B. DuHadaway et al. profile →
  2. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain
    1993 613 citations George C. Prendergast, Edward B. Ziff et al. profile →
  3. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
    1998 569 citations George C. Prendergast et al. Oncogene profile →
  4. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation
    1991 511 citations George C. Prendergast, Edward B. Ziff et al. profile →
  5. Methylation-Sensitive Sequence-Specific DNA Binding by the c-Myc Basic Region
    1991 510 citations George C. Prendergast, Edward B. Ziff profile →
  6. Discovery of IDO1 Inhibitors: From Bench to Bedside
    2017 428 citations George C. Prendergast, William P. Malachowski et al. Cancer Research profile →
  7. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
    2014 398 citations George C. Prendergast, Courtney Smith et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George C. Prendergast United States 77 11.0k 5.0k 4.3k 3.6k 1.9k 226 19.1k
Michael Platten Germany 59 5.5k 0.5× 3.4k 0.7× 2.7k 0.6× 3.8k 1.0× 2.4k 1.2× 300 15.7k
Christoph W. Turck Germany 64 9.4k 0.9× 2.0k 0.4× 1.6k 0.4× 2.6k 0.7× 1.0k 0.5× 247 16.0k
Benoı̂t J. Van den Eynde Belgium 54 5.0k 0.5× 4.5k 0.9× 2.1k 0.5× 6.9k 1.9× 571 0.3× 119 11.6k
Alexander J. Muller United States 45 3.8k 0.3× 2.0k 0.4× 3.5k 0.8× 2.4k 0.7× 455 0.2× 114 10.0k
Craig J. Thomas United States 61 7.0k 0.6× 1.6k 0.3× 1.5k 0.4× 2.1k 0.6× 1.9k 1.0× 250 15.2k
Paul van der Valk Netherlands 80 5.8k 0.5× 5.4k 1.1× 541 0.1× 3.3k 0.9× 1.1k 0.6× 252 19.5k
Peggy Scherle United States 47 4.6k 0.4× 2.9k 0.6× 771 0.2× 2.9k 0.8× 958 0.5× 154 10.0k
Helga E. de Vries Netherlands 74 6.2k 0.6× 1.8k 0.4× 617 0.1× 3.0k 0.8× 1.4k 0.7× 257 16.8k
Vincent Stroobant Belgium 46 3.9k 0.4× 2.0k 0.4× 1.6k 0.4× 3.6k 1.0× 355 0.2× 106 8.1k
Edward J. Goetzl United States 94 13.6k 1.2× 1.9k 0.4× 256 0.1× 5.8k 1.6× 2.3k 1.2× 380 26.6k

Countries citing papers authored by George C. Prendergast

Since Specialization
Citations

This map shows the geographic impact of George C. Prendergast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George C. Prendergast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George C. Prendergast more than expected).

Fields of papers citing papers by George C. Prendergast

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George C. Prendergast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George C. Prendergast. The network helps show where George C. Prendergast may publish in the future.

Co-authorship network of co-authors of George C. Prendergast

This figure shows the co-authorship network connecting the top 25 collaborators of George C. Prendergast. A scholar is included among the top collaborators of George C. Prendergast based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George C. Prendergast. George C. Prendergast is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Karen, Randy Longman, Adam E. Snook, et al.. (2023). Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15. Nature Communications. 14(1). 7363–7363. 29 indexed citations
2.
Dey, Souvik, Arpita Mondal, James B. DuHadaway, et al.. (2021). IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. 9(5). 514–528. 24 indexed citations
3.
Nevler, Avinoam, Alexander J. Muller, Erika Sutanto‐Ward, et al.. (2018). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research. 25(2). 724–734. 41 indexed citations
4.
DuHadaway, James B., Khoa Pham, Ariel Lewis-Ballester, et al.. (2018). Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162. 455–464. 42 indexed citations
5.
Smith, Courtney, Mee Young Chang, Katherine H. Parker, et al.. (2012). IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery. 2(8). 722–735. 260 indexed citations
6.
Kazerounian, Shiva, Damien Gerald, Minzhou Huang, et al.. (2012). RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Research. 73(1). 50–61. 40 indexed citations
7.
Zhang, Chunyu, Abdel Elkahloun, Hongling Liao, et al.. (2011). Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells. Molecular Cancer Therapeutics. 10(7). 1137–1148. 10 indexed citations
8.
Muller, Alexander J., et al.. (2010). Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. Cancer Research. 70(5). 1845–1853. 52 indexed citations
9.
Metz, Richard, James B. DuHadaway, Sonja Rust, et al.. (2010). Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase. Molecular Cancer Therapeutics. 9(6). 1864–1871. 27 indexed citations
10.
DuHadaway, James B., et al.. (2009). The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity. The Journal of Immunology. 182(12). 7509–7517. 89 indexed citations
11.
Ramalingam, Arivudainambi, James B. DuHadaway, Erika Sutanto‐Ward, et al.. (2008). Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research. 68(6). 1683–1690. 23 indexed citations
12.
Chang, Mee Young, Janette Boulden, Jessica Katz, et al.. (2007). Bin1 Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer. Cancer Research. 67(16). 7605–7612. 61 indexed citations
13.
Metz, Richard, James B. DuHadaway, Uma Kamasani, et al.. (2007). Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d -1-Methyl-Tryptophan. Cancer Research. 67(15). 7082–7087. 387 indexed citations
14.
Chang, Mee Young, Janette Boulden, Erika Sutanto‐Ward, et al.. (2007). Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research. 67(1). 100–107. 36 indexed citations
15.
Muller, Alexander J., Madhav Sharma, James B. DuHadaway, et al.. (2007). Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 67(2). 792–801. 467 indexed citations
16.
Routhier, Eric, Preston S. Donover, & George C. Prendergast. (2003). hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene. 22(5). 637–648. 23 indexed citations
17.
Lebowitz, Peter F. & George C. Prendergast. (1998). Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17(11). 1439–1445. 179 indexed citations
18.
Wechsler‐Reya, Robert J., Katherine J. Elliott, & George C. Prendergast. (1998). A Role for the Putative Tumor Suppressor Bin1 in Muscle Cell Differentiation. Molecular and Cellular Biology. 18(1). 566–575. 102 indexed citations
19.
Carmeliet, Peter, L Kieckens, Luc Schoonjans, et al.. (1993). Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.. Journal of Clinical Investigation. 92(6). 2746–2755. 292 indexed citations
20.
Prendergast, George C. & Edward B. Ziff. (1992). A new bind for Myc. Trends in Genetics. 8(3). 91–96. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Platten Breakdown of academic impact, for papers by Christoph W. Turck Breakdown of academic impact, for papers by Benoı̂t J. Van den Eynde Breakdown of academic impact, for papers by Alexander J. Muller Breakdown of academic impact, for papers by Craig J. Thomas Breakdown of academic impact, for papers by Paul van der Valk Breakdown of academic impact, for papers by Peggy Scherle Breakdown of academic impact, for papers by Helga E. de Vries Breakdown of academic impact, for papers by Vincent Stroobant Breakdown of academic impact, for papers by Edward J. Goetzl
Rankless by CCL
2026